Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leukemia drug repurposed to tackle resistant lung cancer

NCT ID NCT07140016

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 41 times

Summary

This early-stage trial tests gilteritinib, a drug already approved for a type of leukemia, in about 40 adults with advanced ALK-positive non-small cell lung cancer whose tumors no longer respond to standard ALK inhibitors. Participants take a daily tablet, and the main goal is to see if the drug is safe and tolerable. The study will also track whether tumors shrink, but it is too early to know if this will become a new treatment option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • OSF Health Care

    RECRUITING

    Peoria, Illinois, 61637, United States

  • Site ES34006

    RECRUITING

    Madrid, Spain

  • Site ES34008

    RECRUITING

    Málaga, Spain

  • Site ES34011

    RECRUITING

    Madrid, Spain

  • Site ES34017

    RECRUITING

    Barcelona, Spain

  • Site FR33001

    RECRUITING

    Villejuif, France

  • Site FR33005

    RECRUITING

    Toulouse, France

  • Site FR33008

    RECRUITING

    Saint-Herblain, France

  • UT Southwestern Medical Center at Dallas

    RECRUITING

    Dallas, Texas, 75390, United States

  • University of California - Irvine

    RECRUITING

    Orange, California, 92868, United States

  • University of Michigan Health Systems

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Virginia Cancer Specialists PC

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

gilteritinib (tablet)

What this could lead to

If it works, this could offer a new treatment option for people with ALK-positive lung cancer whose current drugs have stopped working.

What could go wrong

This is a very early (Phase 1b) and small (40 people) study focused on safety, not yet on effectiveness. The drug may not shrink tumors or may cause side effects that limit its use.

Conditions

The condition(s) this trial relates to.

ALK-positive anaplastic large cell lymphoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) NON-SMALL CELL LUNG CANCER (NSCLC)